$FBIO
Fortress Biotech, Inc. Stock $fbio

$fbio Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000114420415047739 Filed on August 10, 2015

Income Statement

Concept	2015 Q3	2015 Q2	2014 Q4
Revenue	$25.00K	$0.00	$0.00
YoY Change
Cost Of Revenue	$0.00	$0.00
YoY Change
Gross Profit	$25.00K	$0.00
YoY Change
Gross Profit Margin	100.0%
Selling, General & Admin	$8.079M	$4.530M	$3.200M
YoY Change	194.85%	89.54%	7.74%
% of Gross Profit	32316.0%
Research & Development	$9.073M	$2.411M	$1.770M
YoY Change	463.89%	1.43%	-72.98%
% of Gross Profit	36292.0%
Depreciation & Amortization	$6.000K	$5.000K	$0.00
YoY Change	0.0%	-16.67%	-100.0%
% of Gross Profit	24.0%
Operating Expenses	$18.10M	$7.762M	$4.960M
YoY Change	316.41%	62.96%	-47.9%
Operating Profit	-$18.10M	-$7.762M	-$4.961M
YoY Change	316.41%	62.96%	-47.91%
Interest Expense	$350.0K	$352.0K	$1.250M
YoY Change	189.26%	195.8%	-562.96%
% of Operating Profit
Other Income/Expense, Net	-$1.783M	$1.344M
YoY Change	624.8%	2484.62%
Pretax Income	-$19.86M	-$6.420M	-$3.710M
YoY Change	332.68%	36.31%	-62.14%
Income Tax
% Of Pretax Income
Net Earnings	-$18.16M	-$6.175M	-$3.713M
YoY Change	295.49%	31.08%	-62.1%
Net Earnings / Revenue	-72644.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$460.8K	-$158.0K	-$99.30K
COMMON SHARES
Basic Shares Outstanding	46.83M shares		44.31M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q3	2015 Q2	2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$69.61M	$66.60M	$73.92M
YoY Change	-2.78%	-12.48%	-25.71%
Cash & Equivalents	$25.56M	$41.04M	$49.76M
Short-Term Investments	$44.05M	$25.57M	$24.16M
Other Short-Term Assets	$1.100M	$1.000M	$700.0K
YoY Change	175.0%	150.0%	40.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$66.60M	$62.03M	$70.46M
YoY Change	-7.59%	-18.91%	-29.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$100.0K	$90.00K	$52.00K
YoY Change	72.41%	-10.0%	-88.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$250.0K	$250.0K	$250.0K
YoY Change	-16.67%	-16.67%
Other Assets	$14.80M	$172.0K	$64.00K
YoY Change	8076.8%	-98.78%	-38.46%
Total Long-Term Assets	$20.26M	$21.67M	$18.86M
YoY Change	27.17%	50.45%	3323.23%
TOTAL ASSETS
Total Short-Term Assets	$66.60M	$62.03M	$70.46M
Total Long-Term Assets	$20.26M	$21.67M	$18.86M
Total Assets	$86.86M	$83.70M	$89.33M
YoY Change	-1.3%	-7.92%	-11.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.287M	$583.0K	$366.0K
YoY Change	286.49%	94.33%	-21.79%
Accrued Expenses	$7.137M	$4.386M	$3.683M
YoY Change	123.03%	41.48%	-16.86%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.450M	$4.995M	$4.077M
YoY Change	137.56%	45.33%	-63.63%
LONG-TERM LIABILITIES
Long-Term Debt	$23.30M	$23.20M	$14.00M
YoY Change	66.43%	65.71%	100.0%
Other Long-Term Liabilities	$202.0K	$264.0K	$722.0K
YoY Change	-74.53%	-64.99%	-32.96%
Total Long-Term Liabilities	$202.0K	$264.0K	$722.0K
YoY Change	-82.9%	-75.0%	-32.96%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.450M	$4.995M	$4.077M
Total Long-Term Liabilities	$202.0K	$264.0K	$722.0K
Total Liabilities	$31.94M	$28.49M	$18.80M
YoY Change	70.39%	53.99%	-2.6%
SHAREHOLDERS EQUITY
Retained Earnings	-$178.1M	-$160.0M	-$141.7M
YoY Change	29.06%	19.89%	16.8%
Common Stock	$47.00K	$47.00K	$46.00K
YoY Change	6.82%	6.82%	15.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$53.60M	$55.88M	$70.52M
YoY Change
Total Liabilities & Shareholders Equity	$86.86M	$83.70M	$89.33M
YoY Change	-1.3%	-7.92%	-11.19%

Cashflow Statement

Concept	2015 Q3	2015 Q2	2014 Q4
OPERATING ACTIVITIES
Net Income	-$18.16M	-$6.175M	-$3.713M
YoY Change	295.49%	31.08%	-62.1%
Depreciation, Depletion And Amortization	$6.000K	$5.000K	$0.00
YoY Change	0.0%	-16.67%	-100.0%
Cash From Operating Activities	-$15.17M	-$6.160M	-$3.520M
YoY Change	457.72%	53.23%	-50.7%
INVESTING ACTIVITIES
Capital Expenditures	-$40.00K	-$50.00K	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$11.33M	-$1.700M	-$22.67M
YoY Change	22560.0%	466.67%	15013.33%
Cash From Investing Activities	-$11.37M	-$1.750M	-$22.67M
YoY Change	22640.0%	483.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	11.07M	30.00K	4.370M
YoY Change	-868.75%	-76.92%	1020.51%
NET CHANGE
Cash From Operating Activities	-15.17M	-6.160M	-3.520M
Cash From Investing Activities	-11.37M	-1.750M	-22.67M
Cash From Financing Activities	11.07M	30.00K	4.370M
Net Change In Cash	-15.47M	-7.880M	-21.82M
YoY Change	267.46%	88.07%	223.26%
FREE CASH FLOW
Cash From Operating Activities	-$15.17M	-$6.160M	-$3.520M
Capital Expenditures	-$40.00K	-$50.00K	$0.00
Free Cash Flow	-$15.13M	-$6.110M	-$3.520M
YoY Change	456.25%	51.99%	-51.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	20000000	USD
CY2014Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	20002000	USD
CY2015Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	14586000	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Trading Symbol TradingSymbol	FBIO
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	46833715	shares
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49759000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	702000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	70463000	USD
CY2015Q2	us-gaap	Assets Assets	83699000	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4995000	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-159959000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	14586000	USD
CY2015Q2	us-gaap	Long Term Investments LongTermInvestments	5567000	USD
CY2014Q4	us-gaap	Long Term Investments LongTermInvestments	4160000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1250000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2377000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2411000	USD
	us-gaap	Operating Expenses OperatingExpenses	20333000	USD
	us-gaap	Operating Expenses OperatingExpenses	11346000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	880000	USD
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2386000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4763000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-7762000	USD
CY2014Q2	fbio	Accretion And Interest Expenses AccretionAndInterestExpenses	119000	USD
CY2015Q2	fbio	Accretion And Interest Expenses AccretionAndInterestExpenses	352000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-4711000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-6175000	USD
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36005294	shares
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39119606	shares
CY2014Q2	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	0	USD
CY2015Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	74000	USD
CY2014Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	171000	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	7762000	USD
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1344000	USD
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	52000	USD
CY2015Q2	us-gaap	Profit Loss ProfitLoss	-6418000	USD
CY2014Q2	us-gaap	Profit Loss ProfitLoss	-4711000	USD
CY2015Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-243000	USD
CY2014Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2015Q2	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1548000	USD
CY2014Q2	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6865000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4066000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4481000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7280000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-19833000	USD
	fbio	Accretion And Interest Expenses AccretionAndInterestExpenses	1085000	USD
	fbio	Accretion And Interest Expenses AccretionAndInterestExpenses	683000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-12081000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35953234	shares
	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	0	USD
	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	1407000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	156000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	350000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-735000	USD
	us-gaap	Profit Loss ProfitLoss	-18953000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-722000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	8987000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3395000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2598000	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	167000	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	555000	USD
	us-gaap	Trading Securities Unrealized Holding Gain Loss TradingSecuritiesUnrealizedHoldingGainLoss	0	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-84000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1486000	USD
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-398000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10088000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-545000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	606000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	32000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	13655000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	14009000	USD
	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	14009000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-13090000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-23723000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	75798000	USD
	us-gaap	Interest Paid InterestPaid	614000	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	4000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	9000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	723000	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-50000	USD
CY2015Q2	us-gaap	Long Term Debt LongTermDebt	24009000	USD
CY2014Q4	us-gaap	Long Term Debt LongTermDebt	14009000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	143000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	94000	USD
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	53000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	42000	USD
CY2014Q4	us-gaap	Capital Leases Future Minimum Payments Receivable Current CapitalLeasesFutureMinimumPaymentsReceivableCurrent	500000	USD
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	167000	USD
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	75000	USD
CY2015Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	640000	USD
CY2014Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	598000	USD
CY2015Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	359000	USD
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	837000	USD
CY2015Q2	fbio	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	623000	USD
CY2014Q4	fbio	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	832000	USD
CY2015Q2	fbio	Other Short Term Liabilities Related To Manufacturing Rights OtherShortTermLiabilitiesRelatedToManufacturingRights	1500000	USD
CY2014Q4	fbio	Other Short Term Liabilities Related To Manufacturing Rights OtherShortTermLiabilitiesRelatedToManufacturingRights	1000000	USD
CY2015Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	593000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	213000	USD
CY2015Q2	fbio	Other Long Term Liabilities Related To Manufacturing Rights OtherLongTermLiabilitiesRelatedToManufacturingRights	0	USD
CY2014Q4	fbio	Other Long Term Liabilities Related To Manufacturing Rights OtherLongTermLiabilitiesRelatedToManufacturingRights	334000	USD
CY2015Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	120000	USD
CY2015Q2	fbio	Lease Abandonment Non Current LeaseAbandonmentNonCurrent	144000	USD
CY2014Q4	fbio	Lease Abandonment Non Current LeaseAbandonmentNonCurrent	268000	USD
CY2015Q2	us-gaap	Trading Securities TradingSecurities	20000000	USD
CY2015Q2	us-gaap	Equity Method Investments Fair Value Disclosure EquityMethodInvestmentsFairValueDisclosure	5567000	USD
CY2015Q2	us-gaap	Marketable Securities MarketableSecurities	25567000	USD
CY2014Q4	us-gaap	Trading Securities TradingSecurities	20002000	USD
CY2014Q4	us-gaap	Equity Method Investments Fair Value Disclosure EquityMethodInvestmentsFairValueDisclosure	4160000	USD
CY2014Q4	us-gaap	Marketable Securities MarketableSecurities	24162000	USD
CY2014Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	4160000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	0	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	1407000	USD
CY2015Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	5567000	USD
CY2015Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1574000	USD
CY2014Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1463000	USD
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3395000	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2164365000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	100000000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2064365000	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1747698000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.69
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.15
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.82
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.75
CY2015Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1210	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y9M14D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M12D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M17D
CY2015Q2	us-gaap	Revenues Revenues	0	USD
CY2014Q2	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	500000	USD
	us-gaap	Revenues Revenues	0	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	84000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	295000	USD
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	0	USD
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	250000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	49000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2015Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	777000	USD
CY2014Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	6000	USD
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46833715	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46494034	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46833715	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46494034	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt 26.4pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 24.2pt" align="justify"><b><font style="FONT-SIZE: 10pt">Use of Estimates</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt 26.4pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 24.2pt" align="justify"><font style="FONT-SIZE: 10pt">The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value of stock options and warrants, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates. </font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 26.4pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 24.2pt" align="justify"><b><font style="FONT-SIZE: 10pt"> Reclassifications</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 26.4pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 24.2pt" align="justify"><font style="FONT-SIZE: 10pt">The Company reclassified debt issuance costs from other assets to notes payable, long-term, net on the unaudited condensed consolidated balance sheets for all periods presented pursuant to the early adoption of Accounting Standards Update ("ASU") No. 2015-03 - <i> Simplifying the Presentation of Debt Issuance Costs</i>.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	14600000	USD
	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	400000	USD
CY2014Q4	us-gaap	Trading Securities Cost TradingSecuritiesCost	20002000	USD
CY2014	us-gaap	Trading Securities Unrealized Holding Gain Loss TradingSecuritiesUnrealizedHoldingGainLoss	0	USD
CY2015Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	700000	USD
CY2015Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	14300000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P4M24D
CY2015Q2	fbio	Employee Stock Purchase Plan Number Of Shares Purchased By Employees EmployeeStockPurchasePlanNumberOfSharesPurchasedByEmployees	77875	shares
CY2015Q2	fbio	Employee Stock Purchase Plan Number Of Shares Available For Future Sale EmployeeStockPurchasePlanNumberOfSharesAvailableForFutureSale	122125	shares
CY2015Q2	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	8465	USD
CY2014Q2	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	7128	USD
	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	14848	USD
	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	15746	USD
	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	49000	USD
CY2015Q2	us-gaap	Equity Method Investments EquityMethodInvestments	250000	USD
	us-gaap	Fair Value Assumptions Weighted Average Volatility Rate FairValueAssumptionsWeightedAverageVolatilityRate	0.254	pure
CY2015Q2	us-gaap	Share Price SharePrice	9.52
CY2014Q4	us-gaap	Equity Method Investments EquityMethodInvestments	250000	USD
	us-gaap	Investments In And Advances To Affiliates At Fair Value Period Increase Decrease InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease	1400000	USD
CY2015Q2	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	5300000	USD
CY2015Q2	fbio	Working Capital WorkingCapital	500000	USD
CY2015Q2	fbio	Working Capital Committed WorkingCapitalCommitted	100000	USD
CY2015Q2	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	6000	USD
CY2014Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	38000	USD
CY2015Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9679623	shares
CY2015Q2	fbio	Milestone Payments MilestonePayments	500000	USD
CY2014Q4	fbio	Milestone Payments MilestonePayments	0	USD
CY2014Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9188360	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9555712	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8749229	shares
CY2015Q2	fbio	Lease Impairment Current LeaseImpairmentCurrent	165000	USD
CY2014Q4	fbio	Lease Impairment Current LeaseImpairmentCurrent	165000	USD
CY2015Q2	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	38000	USD
CY2015Q2	us-gaap	Depreciation Depreciation	5000	USD
CY2014Q2	us-gaap	Depreciation Depreciation	6000	USD
	us-gaap	Depreciation Depreciation	11000	USD
	us-gaap	Depreciation Depreciation	11000	USD
CY2015Q2	us-gaap	Minority Interest MinorityInterest	-673000	USD
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q2	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	38000	USD
CY2015Q2	us-gaap	Interest Expense InterestExpense	352000	USD
CY2014Q2	us-gaap	Interest Expense InterestExpense	119000	USD
	us-gaap	Interest Expense InterestExpense	683000	USD
	us-gaap	Interest Expense InterestExpense	1085000	USD
	fbio	Percentage Of Tax Benefit Likely Of Being Realized PercentageOfTaxBenefitLikelyOfBeingRealized	0.5	pure
	us-gaap	Interest Expense Debt InterestExpenseDebt	800000	USD
	us-gaap	Accretion Of Discount AccretionOfDiscount	400000	USD
CY2015Q2	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	44400	USD
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	87700	USD
CY2014Q2	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	38400	USD
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	38400	USD
CY2014Q2	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	400000	USD
CY2015Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.09	pure
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	55881000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	70523000	USD
CY2014Q4	us-gaap	Minority Interest MinorityInterest	0	USD
CY2015Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	55208000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	70523000	USD
	fbio	Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan	26000	USD
	fbio	Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan	0	USD
CY2015Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	23232000	USD
CY2014Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	14003000	USD
CY2015Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	264000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	722000	USD
CY2015Q2	us-gaap	Liabilities Liabilities	28491000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	18802000	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	47000	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	46000	USD
CY2015Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	215793000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	212205000	USD
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	997000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	62034000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	90000	USD
CY2015Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	172000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	64000	USD
CY2014Q4	us-gaap	Assets Assets	89325000	USD
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	583000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	366000	USD
CY2015Q2	us-gaap	Interest Payable Current InterestPayableCurrent	26000	USD
CY2014Q4	us-gaap	Interest Payable Current InterestPayableCurrent	28000	USD
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4386000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3683000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4077000	USD
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	Fortress Biotech, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001429260
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	52000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41037000	USD
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	120000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11346000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-141728000	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	83699000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	89325000	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	4763000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18231000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.47
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38848660	shares
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3803000	USD
CY2015Q2	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	1622000	USD
	us-gaap	Profit Loss ProfitLoss	-12081000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-124000	USD
	us-gaap	Trading Securities Unrealized Holding Gain Loss TradingSecuritiesUnrealizedHoldingGainLoss	-2000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	295000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-2000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	920000	USD
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-16702000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1250000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1407000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	216000	USD
	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	10000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	9387000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-8722000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99521000	USD
	us-gaap	Interest Paid InterestPaid	80000	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	855000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	108000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-624000	USD
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	2598000	USD

Files In Submission

Name	View Source	Status
0001144204-15-047739-index-headers.html	Edgar Link	pending
0001144204-15-047739-index.html	Edgar Link	pending
0001144204-15-047739.txt	Edgar Link	pending
0001144204-15-047739-xbrl.zip	Edgar Link	pending
fbio-20150630.xml	Edgar Link	completed
fbio-20150630.xsd	Edgar Link	pending
fbio-20150630_cal.xml	Edgar Link	unprocessable
fbio-20150630_def.xml	Edgar Link	unprocessable
fbio-20150630_lab.xml	Edgar Link	unprocessable
fbio-20150630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v416497_10q.htm	Edgar Link	pending
v416497_ex31-1.htm	Edgar Link	pending
v416497_ex31-2.htm	Edgar Link	pending
v416497_ex32-1.htm	Edgar Link	pending
v416497_ex32-2.htm	Edgar Link	pending
v416497_ex99-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FBIO
Fortress Biotech, Inc. Stock $fbio

2015 Q3 Form 10-Q Financial Statement

#000114420415047739 Filed on August 10, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO Fortress Biotech, Inc. Stock $fbio

2015 Q3 Form 10-Q Financial Statement

#000114420415047739 Filed on August 10, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO
Fortress Biotech, Inc. Stock $fbio